XML 46 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONCENTRATION OF RISK
3 Months Ended
Mar. 31, 2013
Risks and Uncertainties [Abstract]  
Concentration Risk Disclosure [Text Block]
CONCENTRATION OF RISK

Customer and Credit Risk

The Company provides trade credit to its customers in the normal course of business.  

One payor accounted for approximately 21% and 16% of revenue during the three months ended March 31, 2013 and 2012, respectively. The majority of the revenue is related to the Infusion Services segment.

Therapy Revenue Risk

The Company sells products related to the Immune Globulin therapy, which represented 17% and 21% of revenue during the three months ended March 31, 2013 and 2012, respectively. The revenue is related to the Infusion Services segment.